You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 167 No. 10, May 28, 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Review Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (18)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Evidence-Based Medicine
 •Transplantation
 •Bone Marrow Transplantation
 •Review
 •Cardiovascular Disease/ Myocardial Infarction
 •Congestive Heart Failure/ Cardiomyopathy
 •Alert me on articles by topic

Adult Bone Marrow–Derived Cells for Cardiac Repair

A Systematic Review and Meta-analysis

Ahmed Abdel-Latif, MD; Roberto Bolli, MD; Imad M. Tleyjeh, MD, MSc; Victor M. Montori, MD, MSc; Emerson C. Perin, MD; Carlton A. Hornung, PhD, MPH; Ewa K. Zuba-Surma, PhD; Mouaz Al-Mallah, MD; Buddhadeb Dawn, MD

Arch Intern Med. 2007;167(10):989-997.

Background  The results from small clinical studies suggest that therapy with adult bone marrow (BM)–derived cells (BMCs) reduces infarct size and improves left ventricular function and perfusion. However, the effects of BMC transplantation in patients with ischemic heart disease remains unclear.

Methods  We searched MEDLINE, EMBASE, Science Citation Index, CINAHL (Cumulative Index to Nursing and Allied Health), and the Cochrane Central Register of Controlled Trials (CENTRAL) (through July 2006) for randomized controlled trials and cohort studies of BMC transplantation to treat ischemic heart disease. We conducted a random-effects meta-analysis across eligible studies measuring the same outcomes.

Results  Eighteen studies (N = 999 patients) were eligible. The adult BMCs included BM mononuclear cells, BM mesenchymal stem cells, and BM-derived circulating progenitor cells. Compared with controls, BMC transplantation improved left ventricular ejection fraction (pooled difference, 3.66%; 95% confidence interval [CI], 1.93% to 5.40%; P<.001); reduced infarct scar size (–5.49%; 95% CI, –9.10% to –1.88%; P = .003); and reduced left ventricular end-systolic volume (–4.80 mL; 95% CI, –8.20 to –1.41 mL; P = .006).

Conclusions  The available evidence suggests that BMC transplantation is associated with modest improvements in physiologic and anatomic parameters in patients with both acute myocardial infarction and chronic ischemic heart disease, above and beyond conventional therapy. Therapy with BMCs seems safe. These results support conducting large randomized trials to evaluate the impact of BMC therapy vs the standard of care on patient-important outcomes.


Author Affiliations: Division of Cardiology and the Institute of Molecular Cardiology (Drs Abdel-Latif, Bolli, Zuba-Surma, and Dawn) and Department of Epidemiology and Population Health, School of Public Health and Information Sciences (Dr Hornung), University of Louisville, Louisville, Ky; Knowledge and Encounter Research Unit, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minn (Drs Tleyjeh and Montori); King Fahd Medical City, Riyadh, Saudi Arabia (Dr Tleyjeh); Department of Cardiology, University of Texas, Houston (Dr Perin); and Division of Cardiovascular Imaging, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (Dr Al-Mallah).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Erythropoietin and mesenchymal stromal cells in angiogenesis and myocardial regeneration: one plus one equals three?
Ward and Stewart
Cardiovasc Res 2008;0:cvn153v2-3.
FULL TEXT  

Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review
Martin-Rendon et al.
Eur Heart J 2008;0:ehn220v1-12.
ABSTRACT | FULL TEXT  

Review: Endothelial progenitor cells: markers of vascular reparative capacity
Povsic and Goldschmidt-Clermont
Therapeutic Advances in Cardiovascular Disease 2008;2:199-213.
ABSTRACT  

Transplantation of Bone Marrow-Derived Very Small Embryonic-Like Stem Cells Attenuates Left Ventricular Dysfunction and Remodeling After Myocardial Infarction
Dawn et al.
Stem Cells 2008;26:1646-1655.
ABSTRACT | FULL TEXT  

An Inconvenient Truth: Recognizing Individual Differences in Arteriogenesis
Rehman
Circ. Res. 2008;102:1146-1147.
FULL TEXT  

The Stem Cell Movement
Smart and Riley
Circ. Res. 2008;102:1155-1168.
ABSTRACT | FULL TEXT  

The Management of Heart Failure: The Past, the Present, and the Future
Braunwald
Circ Heart Fail 2008;1:58-62.
FULL TEXT  

Noncanonical Wnt11 Signaling Is Sufficient to Induce Cardiomyogenic Differentiation in Unfractionated Bone Marrow Mononuclear Cells
Flaherty et al.
Circulation 2008;117:2241-2252.
ABSTRACT | FULL TEXT  

Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor for Myocardial Recovery After Acute Myocardial Infarction: A Meta-Analysis
Zohlnhofer et al.
J Am Coll Cardiol 2008;51:1429-1437.
ABSTRACT | FULL TEXT  

The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial: First Randomized Placebo-Controlled Study of Myoblast Transplantation
Menasche et al.
Circulation 2008;117:1189-1200.
ABSTRACT | FULL TEXT  

Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases
Burt et al.
JAMA 2008;299:925-936.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.